We considered the possibility of inflaming a tumor microenvironment by leveraging the few PD-1+ cells that enter the tumors to deliver a Toll-like receptor (TLR) 7/8 agonist, R848 (resiquimod)31. The gene discussed is PDCD1; the disease is neoplasm.